Analgesics Market Report 2025

The analgesics market size has grown steadily in recent years. It will grow from $109.97 billion in 2024 to $113.96 billion in 2025 at a compound annual growth rate (CAGR) of 3.6%. The growth in the historic period can be attributed to alternative therapies impact, safety and efficacy studies, pain prevalence, marketing and promotion, economic factors.

The analgesics market size is expected to see steady growth in the next few years. It will grow to $129.46 billion in 2029 at a compound annual growth rate (CAGR) of 3.2%. The growth in the forecast period can be attributed to pain management alternatives, market competition, consumer health awareness, demographic shifts, rising chronic diseases. Major trends in the forecast period include personalized medicine, non-opioid alternatives, CBD and cannabinoids usage, targeted pain management, accessibility and affordability.

The analgesics market is experiencing significant growth, driven by a notable increase in the prevalence of chronic diseases. Chronic diseases, also known as noncommunicable diseases (NCDs), develop over an extended period due to a combination of genetic, physiological, environmental, and behavioral factors. According to a September 2022 report from the World Health Organization (WHO), NCDs account for 74% of global fatalities, totaling 41 million deaths annually. These diseases result in 17 million premature deaths each year before the age of 70, with 86% occurring in low- and middle-income nations. The escalating prevalence of chronic diseases is a key factor fueling the expansion of the analgesics market as these drugs effectively treat and alleviate severe pain associated with various medical conditions.

The increase in healthcare expenditures is anticipated to drive the growth of the analgesics market in the future. Healthcare expenditures encompass all costs related to providing health services, family planning, nutrition programs, and emergency assistance with a health focus. Rising healthcare spending supports research and development within the pharmaceutical industry for the creation of new and enhanced analgesic medications. For example, in May 2024, the Office for National Statistics, a UK government department, reported that total healthcare spending increased by 5.6% in nominal terms from 2022 to 2023. Consequently, the rise in healthcare expenditures is fueling the growth of the analgesics market.

Companies in the analgesics market are strategically investing to foster growth. Leading manufacturers are channeling investments into clinical-stage companies to enhance their market position and gain a competitive edge. In January 2022, Concentric Analgesics, Inc., secured $20 million in convertible note financing to advance the Phase 3 development of Vocacapsaicin, its lead product candidate for post-surgical pain. Such investments allow companies to expand geographically and attain specialized expertise in research and development, strengthening their overall competitiveness.

Leading companies in the analgesic market are increasingly concentrating on introducing combination analgesics to strengthen their competitive position. Combination analgesics contain a blend of two or more pain-relieving (analgesic) drugs, often designed to provide enhanced pain relief by targeting pain through multiple mechanisms. For instance, in February 2024, UK-based Hikma Pharmaceuticals plc launched COMBOGESIC IV (acetaminophen and ibuprofen) in the United States. This intravenous formulation combines acetaminophen (paracetamol) and ibuprofen, offering dual-action pain relief through the analgesic and anti-inflammatory properties of both drugs. Developed as a non-opioid alternative for pain management, COMBOGESIC IV delivers 1,000 mg of acetaminophen and 300 mg of ibuprofen, providing an effective option amid rising opioid concerns. This formulation offers over twice the pain relief of each component alone, with a quicker onset and a favorable safety profile.

In December 2023, Wellnex Life Limited, an Australian company in the health and wellness sector, acquired Pain Away Ltd. for $22 million. This acquisition aligns with Wellnex's long-term strategy to own brands in stable healthcare segments, strengthening its market position. Pain Away Ltd., a U.S.-based company, specializes in developing and distributing topical pain relief products.

Major companies operating in the analgesics market include Pfizer Inc., Johnson & Johnson Services Inc., Medley Pharmaceuticals Limited, AbbVie Inc., Bayer HealthCare Pharmaceuticals LLC, Novartis International AG, Sanofi SA, Bristol-Myers Squibb Co., AstraZeneca Plc., Abbott Laboratories, GlaxoSmithKline plc, Takeda Pharmaceutical company Limited, Eli Lilly and Company, Reckitt Benckiser Group plc, Viatris Inc., Teva Pharmaceuticals Industries Ltd., Sun Pharmaceutical Industries Limited, Purdue Pharma L.P, Cipla Limited, Allergan Inc., Endo International plc, Amneal Pharmaceuticals LLC, Mallinckrodt Pharmaceuticals Ltd., Chattem Inc., Hisamitsu Pharmaceutical Co.Inc., GW Pharmaceuticals, Verve Health Care Ltd., Alder BioPharmaceuticals Inc., Achelios Therapeutics Inc., WEX Pharmaceuticals Inc., Zynerba Pharmaceuticals, McNeil Consumer & Specialty Medical Products, Innovative Med Concepts LLC.

North America was the largest region in the analgesics market in 2024. Middle East is expected to be the fastest-growing region in the global analgesics market during the forecast period. The regions covered in the analgesics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the analgesics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Analgesics are medications used to alleviate pain, including conditions such as musculoskeletal pain, surgical pain, trauma-induced pain, and cancer-related pain. Examples of analgesics include codeine, hydrocodone, oxycodone, and methadone.

The main types of analgesics are non-opioids and opioids. Non-opioid analgesics are pain relievers available over-the-counter (OTC) and by prescription. They are increasingly promoted as a desirable, safe, and effective first-line therapeutic option in various clinical settings for managing mild to severe acute and chronic pain. Analgesics come in different forms, including prescription analgesics and over-the-counter (OTC) analgesics, with various routes of administration such as oral, intravenous, rectal, transdermal, and topical. They are used both internally (internal analgesics) and externally (external analgesics) and are distributed through channels such as hospital pharmacies, retail pharmacies, and drug stores.

The analgesics market research report is one of a series of new reports that provides analgesics market statistics, including analgesics industry global market size, regional shares, competitors with an analgesics market share, detailed analgesics market segments, market trends, and opportunities, and any further data you may need to thrive in the analgesics industry. This analgesics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The analgesics market consists of sales of codeine, hydrocodone, oxycodone, and methadone. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.